Seaport Therapeutics is a freshly listed neuropsychiatry company trying to turn two clinically known but commercially constrained brain medicines into simple oral drugs, and the second quarter is the first public print after that listing. The Glyph chemistry routes absorption through intestinal lymph rather than the portal vein, which is why allopregnanolone and agomelatine never became straightforward pills. What changed is not a patient efficacy result. What changed is that the company now has a funded public balance sheet and a completed healthy-volunteer package on its second program while the lead depression study continues to enroll.
The tension is that the market is already paying a large premium to cash for platform proof that still sits one step short of a patient endpoint. Cash, cash equivalents, and investments stood at $427 million at mid-year after the upsized offering. Research spending rose to $25 million in the quarter as both programs moved later. Reported general expense jumped because of a one-time non-cash stock award tied to the listing, not because cash overhead suddenly exploded. Shareholders are funding two late-stage paths with a cash pile that management says covers operating plans into 2029.
The quarter's evidence is pharmacokinetic, not therapeutic. GlyphAgo posted a nearly seven-fold bioavailability gain versus unmodified agomelatine and no liver-related adverse events across the Phase 1 program. GlyphAllo's potentially registration-enabling depression study remains on its enrollment plan, with a driving-simulation readout scheduled before that efficacy print. The open question is whether lymphatic delivery that works in healthy volunteers also moves depression and anxiety scores in patients.